Chromothripsis is a one-step genome-shattering catastrophe resulting from disruption of one or few chromosomes in multiple fragments and consequent random rejoining and repair. This study defines incidence of chromothripsis in 395 newly diagnosed adult acute myeloid leukemia (AML) patients from three institutions, its impact on survival and its genomic background. SNP 6.0 or CytoscanHD Array (Affymetrix®) were performed on all samples. We detected chromothripsis with a custom algorithm in 26/395 patients. Patients harboring chromothripsis had higher age (p = 0.002), ELN high risk (HR) (p < 0.001), lower white blood cell (WBC) count (p = 0.040), TP53 loss, and/or mutations (p < 0.001) while FLT3 (p = 0.025), and NPM1 (p = 0.032) mutations were mutually exclusive with chromothripsis. Chromothripsis-positive patients showed a worse overall survival (OS) (p < 0.001) compared with HR patients (p = 0.011) and a poor prognosis in a COX-HR optimal regression model. Chromothripsis presented the hallmarks of chromosome instability [i.e., TP53 alteration, 5q deletion, higher mean of copy number alteration (CNA), complex karyotype, alterations in DNA repair, and cell cycle] and focal deletions on chromosomes 4, 7, 12, 16, and 17. CBA. FISH showed that chromothripsis is associated with marker, derivative, and ring chromosomes. In conclusion, chromothripsis frequently occurs in AML (6.6%) and influences patient prognosis and disease biology.

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Wien Austria

Department of Internal Medicine Hematology and Oncology Masaryk University and Hospital Brno Czech Republic

Department of Pathology St Jude Children's Research Hospital Memphis TN USA

Division of Hematology and Oncology Medical University of Innsbruck Innsbruck Austria

Institute of Hematology L and A Seràgnoli University of Bologna Bologna Italy

MLL Munich Leukemia Laboratory Munich Germany

Zobrazit více v PubMed

Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood. 2002;100:4325–36. doi: 10.1182/blood-2002-03-0772. PubMed DOI

Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer. 2005;43:227–38. doi: 10.1002/gcc.20193. PubMed DOI

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. doi: 10.1182/blood-2016-08-733196. PubMed DOI PMC

Meyerson M, Pellman D. Cancer genomes evolve by pulverizing single chromosomes. Cell. 2011;144:9–10. doi: 10.1016/j.cell.2010.12.025. PubMed DOI

Liu P, Erez A, Nagamani SCS, Dhar SU, Kolodziejska KE, Dharmadhikari AV, et al. Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements. Cell. 2011;146:889–903. doi: 10.1016/j.cell.2011.07.042. PubMed DOI PMC

Boeva V, Jouannet S, Daveau R, Combaret V, Pierre-Eugène C, Cazes A, et al. Breakpoint features of genomic rearrangements in neuroblastoma with unbalanced translocations and chromothripsis. PLoS ONE. 2013;8:e72182. doi: 10.1371/journal.pone.0072182. PubMed DOI PMC

Tapia-Laliena MA, Korzeniewski N, Hohenfellner M, Duensing S. High-risk prostate cancer: a disease of genomic instability. Urol Oncol. 2014;32:1101–7. doi: 10.1016/j.urolonc.2014.02.005. PubMed DOI

Furgason JM, Koncar RF, Michelhaugh SK, Sarkar FH, Mittal S, Sloan AE, et al. Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma. Oncoscience. 2015;2:618–28. doi: 10.18632/oncoscience.178. PubMed DOI PMC

Rausch T, Jones DTW, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012;148:59–71. doi: 10.1016/j.cell.2011.12.013. PubMed DOI PMC

Kloosterman WP, Koster J, Molenaar JJ. Prevalence and clinical implications of chromothripsis in cancer genomes. Curr Opin Oncol. 2014;26:64–72. doi: 10.1097/CCO.0000000000000038. PubMed DOI

Nones K, Waddell N, Wayte N, Patch AM, Bailey P, Newell F, et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun. 2014;5:5224. doi: 10.1038/ncomms6224. PubMed DOI PMC

Przybytkowski E, Lenkiewicz E, Barrett MT, Klein K, Nabavi S, Greenwood CMT, et al. Chromosome-breakage genomic instability and chromothripsis in breast cancer. BMC Genom. 2014;15:579. doi: 10.1186/1471-2164-15-579. PubMed DOI PMC

Hirsch D, Kemmerling R, Davis S, Camps J, Meltzer PS, Ried T, et al. Chromothripsis and focal copy number alterations determine poor outcome in malignant melanoma. Cancer Res. 2013;73:1454–60. doi: 10.1158/0008-5472.CAN-12-0928. PubMed DOI PMC

Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood. 2011;118:675–8. doi: 10.1182/blood-2011-03-344069. PubMed DOI PMC

Bochtler T, Granzow M, Stölzel F, Kunz C, Mohr B, Kartal-Kaess M, et al. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. Blood. 2017;129:1333–42. doi: 10.1182/blood-2016-09-738161. PubMed DOI

Mackinnon RN, Campbell LJ. Chromothripsis under the microscope: a cytogenetic perspective of two cases of AML with catastrophic chromosome rearrangement. Cancer Genet. 2013;206:238–51. doi: 10.1016/j.cancergen.2013.05.021. PubMed DOI

Forero-Castro M, Robledo C, Benito R, Abáigar M, África Martín A, Arefi M, et al. Genome-wide DNA copy number analysis of acute lymphoblastic leukemia identifies new genetic markers associated with clinical outcome. PLoS ONE. 2016;11:e0148972. doi: 10.1371/journal.pone.0148972. PubMed DOI PMC

Ratnaparkhe M, Hlevnjak M, Kolb T, Jauch A, Maass KK, Devens F, et al. Genomic profiling of acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. Leukemia. 2017;31:2048–56. doi: 10.1038/leu.2017.55. PubMed DOI

Bassaganyas L, Bea S, Escaramis G, Tornador C, Salaverria I, Zapata L, et al. Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis. Leukemia. 2013;27:2376–9. doi: 10.1038/leu.2013.127. PubMed DOI PMC

Bertelsen B, Nazaryan-Petersen L, Sun W, Mehrjouy MM, Xie G, Chen W, et al. A germline chromothripsis event stably segregating in 11 individuals through three generations. Genet Med. 2015;18:494–500. doi: 10.1038/gim.2015.112. PubMed DOI

Cai H, Kumar N, Bagheri HC, von Mering C, Robinson MD, Baudis M. Chromothripsis-like patterns are recurring but heterogeneously distributed features in a survey of 22,347 cancer genome screens. BMC Genom. 2014;15:82. doi: 10.1186/1471-2164-15-82. PubMed DOI PMC

Donley N, Thayer MJ. DNA replication timing, genome stability and cancer: late and/or delayed DNA replication timing is associated with increased genomic instability. Semin Cancer Biol. 2013;23:80–9. doi: 10.1016/j.semcancer.2013.01.001. PubMed DOI PMC

Liu G, Stevens JB, Horne SD, Abdallah BY, Ye KJ, Bremer SW, et al. Genome chaos: survival strategy during crisis. Cell Cycle. 2014;13:528–37. doi: 10.4161/cc.27378. PubMed DOI PMC

Mardin BR, Drainas AP, Waszak SM, Weischenfeldt J, Isokane M, Stütz AM, et al. A cell-based model system links chromothripsis with hyperploidy. Mol Syst Biol. 2015;11:828. doi: 10.15252/msb.20156505. PubMed DOI PMC

Maciejowski J, Li Y, Bosco N, Campbell PJ, de Lange T. Chromothripsis and kataegis induced by telomere crisis. Cell. 2015;163:1641–54. doi: 10.1016/j.cell.2015.11.054. PubMed DOI PMC

Jacoby MA, De Jesus Pizarro RE, Shao J, Koboldt DC, Fulton RS, Zhou G, et al. The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. Leukemia. 2014;28:1242–51. doi: 10.1038/leu.2013.368. PubMed DOI PMC

Govind SK, Zia A, Hennings-Yeomans PH, Watson JD, Fraser M, Anghel C, et al. ShatterProof: operational detection and quantification of chromothripsis. BMC Bioinforma. 2014;15:78. doi: 10.1186/1471-2105-15-78. PubMed DOI PMC

Korbel JO, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. Cell. 2013;152:1226–36. doi: 10.1016/j.cell.2013.02.023. PubMed DOI

Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144:27–40. doi: 10.1016/j.cell.2010.11.055. PubMed DOI PMC

Kovtun IV, Murphy SJ, Johnson SH, Cheville JC, Vasmatzis G. Chromosomal catastrophe is a frequent event in clinically insignificant prostate cancer. Oncotarget. 2015;6:29087–96. doi: 10.18632/oncotarget.4900. PubMed DOI PMC

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–405. PubMed

World Medical Association. World Medical Association Declaration of Helsinki. JAMA. 2013;310:2191. doi: 10.1001/jama.2013.281053. PubMed DOI

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81. doi: 10.1016/j.jbi.2008.08.010. PubMed DOI PMC

Parkin B, Erba H, Ouillette P, Roulston D, Purkayastha A, Karp J, et al. Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood. 2010;116:4958–67. doi: 10.1182/blood-2010-01-266999. PubMed DOI PMC

R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016.

Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2016;44:D481–7. doi: 10.1093/nar/gkv1351. PubMed DOI PMC

Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87:89–99. doi: 10.1002/ajh.22246. PubMed DOI

Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19:1639–45. doi: 10.1101/gr.092759.109. PubMed DOI PMC

Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016;122:3484–91. doi: 10.1002/cncr.30203. PubMed DOI PMC

Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017;31:705–11. doi: 10.1038/leu.2016.263. PubMed DOI

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21. doi: 10.1056/NEJMoa1516192. PubMed DOI PMC

Zhang CZ, Spektor A, Cornils H, Francis JM, Jackson EK, Liu S, et al. Chromothripsis from DNA damage in micronuclei. Nature. 2015;522:179–84. doi: 10.1038/nature14493. PubMed DOI PMC

Leibowitz ML, Zhang CZ, Pellman D. Chromothripsis: a new mechanism for rapid karyotype evolution. Annu Rev Genet. 2015;49:183–211. doi: 10.1146/annurev-genet-120213-092228. PubMed DOI

Poot M, Haaf T. Mechanisms of origin, phenotypic effects and diagnostic implications of complex chromosome rearrangements. Mol Syndromol. 2015;6:110–34. doi: 10.1159/000438812. PubMed DOI PMC

Tischkowitz MD, Morgan NV, Grimwade D, Eddy C, Ball S, Vorechovsky I, et al. Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia. 2004;18:420–5. doi: 10.1038/sj.leu.2403280. PubMed DOI

Ghelli Luserna di Rora’ A, Iacobucci I, Martinelli G. The cell cycle checkpoint inhibitors in the treatment of leukemias. J Hematol Oncol. 2017;10:77. doi: 10.1186/s13045-017-0443-x. PubMed DOI PMC

Röllig C, Bornhäuser M, Thiede C, Taube F, Kramer M, Mohr B, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol J Am Soc Clin Oncol. 2011;29:2758–65. doi: 10.1200/JCO.2010.32.8500. PubMed DOI

Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability